Provided by Tiger Trade Technology Pte. Ltd.

ASCLETIS-B

16.270
+1.83012.67%
Volume:9.22M
Turnover:147.09M
Market Cap:17.26B
PE:-54.15
High:16.340
Open:14.500
Low:14.460
Close:14.440
52wk High:18.750
52wk Low:4.090
Shares:1.06B
HK Float Shares:1.06B
Volume Ratio:5.94
T/O Rate:0.87%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.300
ROE:-12.77%
ROA:-12.32%
PB:8.17
PE(LYR):-54.15
PS:6455.82

Loading ...

HKEX Share Buyback Summary | December 17

Stock News
·
Dec 17, 2025

ASCLETIS-B (01672) Repurchases 200,000 Shares for HK$2.6099 Million on December 16

Stock News
·
Dec 16, 2025

Ascletis Pharma Inc. repurchases 4,586,000 shares for approximately HK$54.28 million

Reuters
·
Dec 16, 2025

Ascletis Pharma Inc - Ups Share Repurchase Fund to HK$500 Mln

THOMSON REUTERS
·
Dec 16, 2025

ASCLETIS-B (01672) Rebounds Nearly 3% as IL-17 Inhibitor ASC50 Achieves Positive Topline Results in US Phase I Study

Stock News
·
Dec 16, 2025

Ascletis Pharma's Autoimmune Disease Drug Trial Shows Positive Topline Results

MT Newswires Live
·
Dec 15, 2025

Ascletis Announces Positive Topline Results From U.S. Phase I Study of Asc50, a Potential Best-in-Class Oral Small Molecule Il-17 Inhibitor

THOMSON REUTERS
·
Dec 15, 2025

Ascletis Pharma Inc - Asc50 Safe and Well Tolerated at All Dose Levels

THOMSON REUTERS
·
Dec 15, 2025

ASCLETIS-B (01672): Positive Topline Results from US Phase I Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor

Stock News
·
Dec 15, 2025

Ascletis Pharma Reports Positive Phase I Results for Oral IL-17 Inhibitor ASC50

Reuters
·
Dec 15, 2025

Hong Kong Stocks Open Lower: Hang Seng Index Down 1%, Pharmaceutical Sector Leads Declines with ASCLETIS-B (01672) Dropping Over 5%

Stock News
·
Dec 15, 2025

ASCLETIS-B (01672) Repurchases 300,000 Shares for Approximately HK$4.37 Million on December 12

Stock News
·
Dec 12, 2025

Ascletis Pharma Repurchases 300,000 Shares at HK$14.8 Each, Files Disclosure with HKEX

Reuters
·
Dec 12, 2025

Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (Asc40), a First-in-Class Fasn Inhibitor for Acne Treatment

THOMSON REUTERS
·
Dec 10, 2025

ASCLETIS-B (01672): First-in-Class FASN Inhibitor Denifanstat (ASC40) NDA for Acne Treatment Accepted by China NMPA

Stock News
·
Dec 10, 2025

China NMPA Accepts New Drug Application for Ascletis Pharma's Denifanstat for Acne Treatment

Reuters
·
Dec 10, 2025

Ascletis Pharma Inc - Nmpa Acceptance of Nda for Denifanstat

THOMSON REUTERS
·
Dec 10, 2025

Shares of Chinese Drugmaker Ascletis Rise on Weight-Loss Drug Results

Dow Jones
·
Dec 09, 2025

Citi: Ascletis-B's ASC30 Phase IIa Data Further Demonstrates Best-in-Class Potential, Reiterates "Buy/High Risk" Rating

Deep News
·
Dec 09, 2025

Hong Kong Stocks Narrowly Fluctuate; ASCLETIS-B Surges Over 23% on Positive News

Deep News
·
Dec 09, 2025